{"entity":{"type":"insider","cik":"0001664852","url":"/insider/0001664852","json_url":"/insider/0001664852.json","name":"Requadt Scott","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":6,"n_filings":5,"first":"2018-07-02","last":"2022-08-02","span_basis":"filed_date"},"name_variants":[{"name":"Requadt Scott","source":"filing","n_filings":5,"first_seen":"2018-07-02","last_seen":"2022-08-02"}],"transactions":[{"id":6167284,"accession":"0000899243-22-027404","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-027404","line_url":"/filing/0000899243-22-027404#line-1","is_derivative":false,"issuer_cik":"0001664852","issuer_name":"Talaris Therapeutics, Inc.","issuer_ticker":"TALS","issuer_name_source":null,"issuer_url":"/issuer/0001664852","owner_cik":"0001664852","owner_name":"Requadt Scott","owner_display_name":"Requadt Scott","owner_url":"/insider/0001664852","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":39382.0,"shares_display":"39,382","price_per_share":4.25,"price_display":"4.25","price_state":"stated","total_value":167373.5,"total_display":"167,373.50","total_whole":"167,374","shares_owned_after":508680.0,"shares_owned_after_display":"508,680","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-29","filed_date":"2022-08-02","scope":"insider"},{"id":6443737,"accession":"0000899243-22-026986","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-026986","line_url":"/filing/0000899243-22-026986#line-2","is_derivative":false,"issuer_cik":"0001664852","issuer_name":"Talaris Therapeutics, Inc.","issuer_ticker":"TALS","issuer_name_source":null,"issuer_url":"/issuer/0001664852","owner_cik":"0001664852","owner_name":"Requadt Scott","owner_display_name":"Requadt Scott","owner_url":"/insider/0001664852","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3090.0,"shares_display":"3,090","price_per_share":4.25,"price_display":"4.25","price_state":"stated","total_value":13132.5,"total_display":"13,132.50","total_whole":"13,133","shares_owned_after":469298.0,"shares_owned_after_display":"469,298","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-28","filed_date":"2022-07-28","scope":"insider"},{"id":6443734,"accession":"0000899243-22-026986","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-026986","line_url":"/filing/0000899243-22-026986#line-1","is_derivative":false,"issuer_cik":"0001664852","issuer_name":"Talaris Therapeutics, Inc.","issuer_ticker":"TALS","issuer_name_source":null,"issuer_url":"/issuer/0001664852","owner_cik":"0001664852","owner_name":"Requadt Scott","owner_display_name":"Requadt Scott","owner_url":"/insider/0001664852","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5528.0,"shares_display":"5,528","price_per_share":4.24,"price_display":"4.24","price_state":"stated","total_value":23438.72,"total_display":"23,438.72","total_whole":"23,439","shares_owned_after":466208.0,"shares_owned_after_display":"466,208","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-26","filed_date":"2022-07-28","scope":"insider"},{"id":6236036,"accession":"0000899243-22-026759","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-026759","line_url":"/filing/0000899243-22-026759#line-1","is_derivative":false,"issuer_cik":"0001664852","issuer_name":"Talaris Therapeutics, Inc.","issuer_ticker":"TALS","issuer_name_source":null,"issuer_url":"/issuer/0001664852","owner_cik":"0001664852","owner_name":"Requadt Scott","owner_display_name":"Requadt Scott","owner_url":"/insider/0001664852","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9444.0,"shares_display":"9,444","price_per_share":3.7497,"price_display":"3.75","price_state":"stated","total_value":35412.1668,"total_display":"35,412.17","total_whole":"35,412","shares_owned_after":460680.0,"shares_owned_after_display":"460,680","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-22","filed_date":"2022-07-26","scope":"insider"},{"id":6238165,"accession":"0001209191-18-053534","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-053534","line_url":"/filing/0001209191-18-053534#line-4","is_derivative":false,"issuer_cik":"0001249153","issuer_name":"Entasis Therapeutics Holdings Inc.","issuer_ticker":"ETTX","issuer_name_source":null,"issuer_url":"/issuer/0001249153","owner_cik":null,"owner_name":"WHEELER KURT; HENNER DENNIS; Clarus Ventures III, LLC; Simon Nicholas; Clarus Lifesciences III, L.P.; Requadt Scott; Clarus Ventures III GP, L.P.; LIPTAK ROBERT","owner_display_name":"WHEELER KURT","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":453395.0,"shares_display":"453,395","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":6800925.0,"total_display":"6,800,925.00","total_whole":"6,800,925","shares_owned_after":1623405.0,"shares_owned_after_display":"1,623,405","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-09-28","filed_date":"2018-10-02","scope":"insider"},{"id":6000319,"accession":"0001209191-18-040426","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-040426","line_url":"/filing/0001209191-18-040426#line-4","is_derivative":false,"issuer_cik":"0001249153","issuer_name":"Forty Seven, Inc.","issuer_ticker":"FTSV","issuer_name_source":null,"issuer_url":"/issuer/0001249153","owner_cik":null,"owner_name":"Clarus Ventures III GP, L.P.; WHEELER KURT; LIPTAK ROBERT; Requadt Scott; GALAKATOS NICHOLAS; Simon Nicholas; HENNER DENNIS; Clarus Lifesciences III, L.P.; Clarus Ventures III, LLC","owner_display_name":"Clarus Ventures III GP, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":3200000.0,"total_display":"3,200,000.00","total_whole":"3,200,000","shares_owned_after":3816951.0,"shares_owned_after_display":"3,816,951","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-07-02","filed_date":"2018-07-02","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":4,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":4,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":4},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001827506","name":"Talaris Therapeutics, Inc.","url":"/issuer/0001827506","role":"Director, Officer (Chief Executive Officer)","n_filings":3,"first_seen":"2022-07-26","last_seen":"2022-08-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001724344","name":"Entasis Therapeutics Holdings Inc.","url":"/issuer/0001724344","role":"Ten percent owner","n_filings":1,"first_seen":"2018-10-02","last_seen":"2018-10-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001667633","name":"Forty Seven, Inc.","url":"/issuer/0001667633","role":"Ten percent owner","n_filings":1,"first_seen":"2018-07-02","last_seen":"2018-07-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001664852","retrieved_at":"2026-08-23T16:44:57+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}